Association of HY-restricting HLA Class II Alleles, Sex of Firstborn Child, and Pregnancy Outcome in RPL Patients
NCT ID: NCT05342948
Last Updated: 2023-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
583 participants
OBSERVATIONAL
2016-01-01
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that sRPL patients with a first born boy compared to sRPL patients with a firstborn girl who carry ≥1 HY-r HLA class II alleles is associated with a negative prognosis, while no association between sex of firstborn child and pregnancy outcome is expected in sRPL carrying no HY-r HLA class II alleles. Neither do we expect an association between pregnancy outcome and carriage of HY-r HLA class II alleles in pRPL patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microchimerism in Patients With Recurrent Pregnancy Losses
NCT05340556
Genomic Predictors of Recurrent Pregnancy Loss
NCT05444283
Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages
NCT00180804
Molecular Associations With Reproductive Failure
NCT00298116
Study of Gene Associations and Infertility
NCT01223092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These findings were the first of its kind and it has not been confirmed in other cohorts ever since. In a new Danish cohort from another region of Denmark, this study will examine if these findings can be replicated.
Before data collection, a sample size calculation was performed based on the findings in the former studies (Nielsen et al., 2009; Kolte et al., 2016). These studies differ from the present study, since Nielsen et al. (2009) included HLA DRB3\*0301 but not HLA DRB1\*07 as a HY-r allele, and Kolte et al.(2016) included HLA DRB3\*0301 too and measured the cumulative live birth rate in contrast to first pregnancy outcome measured in the present study. However, the sample size calculation based on weighted calculations on results from these studies is the closest we get a suitable sample size for the present study. The sample size in the present study should consist of at least 88 sRPL patients with a first born boy with maternal HY-r HLA class II allele and 73 sRPL patients with a firstborn boy and no maternal HY-r HLA class II alleles on weighted calculations with an alpha level = 0.05, a power of 80 %, and a inclusion ratio of 1.2 more with than without such HLA carriage. The sample size needed to find difference between women with a firstborn boy vs girl with such HLA carriage was smaller; ie. 48 patients for comparing patients with ≥1 HY-r HLA alleles. As this was the primary aim, this sample size was considered sufficient for the study.
Study inclusion started January 1, 2016, and will end when this sample size is reached.
The anticipated sample size of the pRPL group is 1.2 times the total number of sRPL patients since pRPL normally account for about 55 % of RPL patients. Thus, 180 patients are expected in the pRPL, although this is not taking into account when deciding the timing for final follow-up and data collection.
All RPL patients with ≥3 consecutive pregnancy losses admitted to The Center for Recurrent Pregnancy Loss of Western Denmark who do not have significant uterine malformations, prior birth of children of both sexes, or known chromosomal abnormalities will be included. An obstetric and gynecologic history and a routine blood sample will be obtained on all patients at their first visit according to the ESHRE RPL guideline (2018), on which basis the treatment plan will be decided. The majority of patients have a chromosomal analysis on the patient and her partner and all have a 3D ultrasound, HSU or HSG performed.
Both chemical and clinical pregnancies documented in hospital's or practitioner's records are included, while confirmed molar and ectopic pregnancies are not accounted for.
sRPL is defined as ≥3 pregnancy losses after a pregnancy beyond 22 weeks of gestation while pRPL is defined as ≥3 pregnancy losses with no prior pregnancy beyond 22 weeks of gestation.
Only sRPL with birth of children with same sex prior to RPL will be included in the comparison of sRPL patients with previous boy(s) with sRPL patients with previous girl(s) only.
The primary outcome is the association of reproductive outcome in first pregnancy after admission to our RPL Center with the carriage of HY-restricting HLA class II alleles in the following three groups: sRPL having a first born boy and sRPL having a a girl and also in patients with pRPL.
In addition, we will also explore the prevalence of these HY-restricted HLA class II alleles separately and the sex ratio of births after admission in the three groups.
HLA-DRB1 typing is performed based on genetic analyses of peripheral blood as part of the routine work-up at our clinic.
HY restricted HLA class II alleles in our study is defined as DRB1\*01/10 (in strong positive linkage disequilibrium with HLA-DQB1\*0501 ); HLA-DRB1\*15 and HLA-DRB1\*07, which to date have been reported to restrict presentation of HY-antigens.
All data is collected in the RPL clinical database of The RPL Center at Aalborg University Hospital, Denmark (Approval number: 2018-5).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pRPL
Primary RPL patients: no prior birth ≥22 weeks
No interventions assigned to this group
sRPL with a first born boy
Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only boy(s)
No interventions assigned to this group
sRPL with a first born girl
Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only girl(s)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Chromosomal abnormalities
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caroline Nørgaard-Pedersen
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caroline Nørgaard-Pedersen, MD
Role: PRINCIPAL_INVESTIGATOR
Aalborg University Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital
Aalborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kolte AM, Steffensen R, Christiansen OB, Nielsen HS. Maternal HY-restricting HLA class II alleles are associated with poor long-term outcome in recurrent pregnancy loss after a boy. Am J Reprod Immunol. 2016 Nov;76(5):400-405. doi: 10.1111/aji.12561. Epub 2016 Sep 7.
Nielsen HS, Steffensen R, Varming K, Van Halteren AG, Spierings E, Ryder LP, Goulmy E, Christiansen OB. Association of HY-restricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet. 2009 May 1;18(9):1684-91. doi: 10.1093/hmg/ddp077. Epub 2009 Feb 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.